SecProbe.io

CORRESP
1
filename1.htm

    ATTORNEYS
                                         AT LAW

                                                                                777
                                         East Wisconsin Avenue

                                                                                Milwaukee,
                                         WI  53202-5306

                                                                                414.271.2400
                                         TEL

                                                                                414.297.4900
                                         FAX

                                                                                www.foley.com

                                                                                WRITER’S
                                         DIRECT LINE

                                                                                CLIENT/MATTER
                                         NUMBER

                                                                                103159-0101

July
13, 2020

VIA
EDGAR SYSTEM

Ms.
Deborah L. O’Neal

Ms.
Christina DiAngelo Fettig

U.S.
Securities and Exchange Commission

Division
of Investment Management

Washington,
DC 20549

    Re:
    Daxor Corporation,
    Form N-2, File Nos. 333-224509 and 811-22684

Dear
Ms. O’Neal and Ms. Fettig:

On
behalf of our client, Daxor Corporation (“Daxor”), set forth below is Daxor’s response to the comments
of the Staff (the “Staff”) of the Securities and Exchange Commission (the “SEC” or “Commission”),
with respect to the above-referenced filing and Daxor’s annual report on Form N-CSR. The numbered items set forth below
repeat (in bold italics) the comments of the Staff, and following the comments are Daxor’s responses (in regular type).
Daxor is filing herewith an amendment to the registration statement to reflect the comments on the registration statement, and
has requested effectiveness for the registration statement.

We
note that a number of the comments are comments that have been provided in the past. Daxor regrets that these comments were not
adequately addressed, and is taking the following specific steps to ensure that does not happen again with regard to any comments
received from the Staff (the “Enhanced Disclosure Procedure”): (1) meeting with legal counsel to fully understand
the rules and regulations behind the comments; (2) meeting with the independent auditors to go through all of the comments in
detail and the responses; (3) preparing and using a model annual report on Form N-CSR that reflects all of the revisions based
on the Staff comments, annotating the comment behind each of the revisions; (4) ensuring that the model annual report on Form
N-CSR is used to check against each semi-annual and annual report before it is finalized and filed with the Securities and Exchange
Commission; (5) ensuring that the Chief Compliance Officer confirms with legal counsel and the independent auditors that
they have reviewed each semi-annual and annual report and confirmed that they believe it contains the revised disclosure required
by prior comments, and otherwise contains required disclosure; and (6) reviewing and assessing with legal counsel and the independent
auditors whether any of the revised disclosure should be reflected in other filings.

    AUSTIN

        Boston

        CHICAGO

        dallas

        DENVER

    DETROIT

        houston

        JACKSONVILLE

        LOS
        ANGELES

        MADISON

    MEXICO
                                         CITY

        MIAMI

        MILWAUKEE

        NEW
        YORK

        ORLANDO

    SACRAMENTO

        SAN
        DIEGO

        SAN
        FRANCISCO

        SILICON
        VALLEY

        TALLAHASSEE

    TAMPA

        WASHINGTON,
        D.C.

        BRUSSELS

        TOKYO

U.S.
Securities and Exchange Commission

July
13, 2020

Page
2

Registration
Statement Comments

1.
Please confirm no sales have been made since April 30, 2020, and that none will be made until the registration statement
is declared effective, and provide an updated consent.

Response:
Daxor confirms no sales have been made since April 30, 2020, and that none will be made until the registration statement
is declared effective. As requested, Daxor is providing an updated consent with the amendment.

2.
The Fee Table shows Total Annual Expenses after Taxes of 2.85%, but the annual shows 4.26%. Please confirm which is correct. Please
note that tax credits should not go into the Fee Table.

Response:
The Fee Table in the Form N-2 is based on estimated expenses for the year 2020 and reflects the offering done in March 2020. The
estimated expenses reflect a decrease in interest expenses in 2020. Daxor did not include any tax credits in the numbers reflected
in the Fee Table. Daxor has included an updated Fee Table in the filing, based on a review of the amounts.

3.
During the previous financial statement review, the SEC provided the following comment:

We
note the “Investment in Operating Division” on the Schedule of Investments. We remind the Company of the tests required
by Rule 1-02(w) and Rule 3-09 of Regulation S-X to determine if the Company has a significant subsidiary. If the Company has a
significant subsidiary, then Rule 4-08(g) of Regulation S-X requires the presentation of summarized financial information of a
50 percent-or-less owned, significant subsidiary. Please provide the required financial information, or explain why these rules
are not applicable.

Daxor
responded as follows in correspondence dated May 4, 2018:

The
reference to a division is a reference to the Company’s operating business. There is no separate legal entity, just the
Company. The Company will revise this language to avoid the impression that there is a separate legal entity.

The
disclosure on page 9 of the Registration Statement refers to a “wholly owned operating medical device subsidiary,”
please explain whether the operating division is a subsidiary subject to the significance tests of S-X 1-02(w). Are separate financial
statements prepared for the subsidiary? (In addition, page 24 of Daxor’s financial statements discloses that the “rent
expense is allocated to and reflected in the Operating Division’s results of operations which are not part of these financial
statements.”)

U.S.
Securities and Exchange Commission

July
13, 2020

Page
3

Response: The
medical device unit is not a separate legal entity of Daxor, and is not a subsidiary. Daxor is one legal entity and has one general
ledger that consists of the general ledger accounts for the investment accounts and the general ledger accounts for the operating
division. When the independent auditors audit the financial statements, they audit the financial statements of Daxor. The Chief
Financial Officer classifies the operating division accounts as one line item in the financial statements of Daxor and the auditors
audit the whole company. Daxor Corporation does not prepare or have audited separate financial statements for the investment accounts
or the accounts for the operating division. The rent payments are a part of the line item for the operating division accounts.
Daxor has revised the disclosure to delete the reference to the medical device subsidiary, and refer to it as a division.

4.
Review and confirm numbers under “If there is a decrease in the market value of our available for sale securities, this
could have an adverse effect on our ability to fund research and development and marketing activities.” Is the 62.17% based
on net assets? Or a percentage of the portfolio? We counted 24 separate stocks at December 31, 2019, not 32 separate stocks.

Response:
The 62.17% is the percentage of the fair market value of the net assets that is invested in utility common stocks, and the disclosure
in the registration has been revised to reflect this. At December 31, 2019, the portfolio consisted of 22 common stocks, 2 preferred
stocks and 8 call options written, and the disclosure in the registration has been revised to reflect this.

5.
During a previous registration statement review in 2019, the SEC questioned the financial highlights calculations of ratios
to average net assets. The following responses was filed in a response letter dated May 17, 2019:

2.
Please confirm the approach to be taken regarding the financial highlights and the calculation of the “average net assets.”

Response:
The financial highlights were revised to match the numbers used in the annual financial statements, as Daxor and the auditors
believe that revising the disclosure to ensure that “average net assets” are based on the value of net assets determined
no less frequently than the end of each month is not a material change. Going forward, Daxor will ensure that the ratios are calculated
ensuring that “average net assets” are based on the value of net assets determined no less frequently than the end
of each month, in both the registration statement and in the financial statements.

Please
explain whether this change was made to the December 31, 2019 financial highlights calculations as represented in previous
correspondence. If the change was not made, please explain why.

Response:
Daxor will ensure that the ratios are calculated using the “average net assets” based on the value of net assets determined
no less frequently than the end of each month, in future filings. The change was not made, as it should have been, due to an oversight
when preparing the annual report. Daxor has noted the error and believes that the Enhanced Disclosure Procedure will ensure that
in the future filings the ratios will be calculated using the “average net assets” based on the value of net assets
determined no less frequently than the end of each month. Daxor will use the actual numbers in the financial highlights from the
annual report, as Daxor, in consultation with the independent auditors, has determined that revising the disclosure to reflect
the “average net assets” based on the value of net assets determined monthly resulted in a trivial difference.

U.S.
                                         Securities and Exchange Commission

July
13, 2020

Page
4

6.
In the financial highlights, disclose that the total investment return does not reflect sales load, as instructed in Form N-2,
Item 4.1, General Instruction 13.b.

Response:
As requested, Daxor has added this disclosure.

7.
On Page 17: Regarding the disclosure: “We will enter into custodial arrangements for our securities with broker-dealers
who are members of a national securities exchange in accordance with Section 17(f)(1)(B) and Rule 17f-1 of the Investment Company
Act of 1940.” Please modify the disclosure as applicable, as Daxor indicates on the Form N-CEN that Daxor is the only custodian
and checks “Self - rule 17f-2 (17 CFR 270.17f-2)” as the type of custody.

Response:
As requested, Daxor has updated this reference to reflect that Daxor relies on Rule 17f-2.

8.
Please ensure that all documents incorporated by reference are hyperlinked, as required by the amendments adopted by the SEC pursuant
to the FAST Act.

Response:
As requested, Daxor has had the EDGAR coded to provide the hyperlink to any document incorporated by reference.

9.
Please confirm whether Daxor is a personal holding company.

Response:
Daxor, as reported in its annual report, is currently a personal holding company, and Daxor has revised the disclosure in the
registration statement accordingly.

Form
N-CSR Comments

10.
During a previous financial statement review, in correspondence dated May 3, 2019, we noted that the Form N-CEN needs to reflect
the shareholder vote each year, and that the Form N-CSR should reflect the results in accordance with the Investment Company
Act.

Response:
As requested, Daxor will ensure that Form N-CEN reflects the shareholder vote each year and that the Form N-CSR reflects the results
in accordance with the Investment Company Act. Daxor believes that the Enhanced Disclosure Procedure will ensure that this disclosure
is not omitted in the filings.

U.S.
                                         Securities and Exchange Commission

July
13, 2020

Page
5

Note
Items 11 – 18: Daxor notes with regard to the comments in 11 through 18 below, that these same comments were made during
a previous financial statement review, in correspondence dated May 4, 2018. Daxor believes that the Enhanced Disclosure Procedure
will ensure that this disclosure is not omitted in future filings.

11.
Consider disclosing that the “Portfolio Analysis” chart does not include exposure to derivatives.

Response:
In future filings, Daxor will disclose that the “Portfolio Analysis” chart does not include exposure to derivatives.

12.
Please ensure that the Schedule of Investments denotes non-income producing assets in accordance with the requirements of Rule
12-12 of Regulation S-X. And ensure that all applicable footnotes to Rule 12-12 of Regulation S-X have been included, in particular
footnotes 9 and 10.

Response:
In future filings, Daxor will ensure that the Schedule of Investments denotes non-income producing assets in accordance with the
requirements of Rule 12-12 of Regulation S-X.

13.
Please delete the line item “Ratio of net investment income before taxes to average net assets.”

Response:
In future filings, Daxor will delete the line item “Ratio of net investment income before taxes to average net assets.”

14.
Please disclose in the Notes that Daxor follows the accounting and reporting requirements of investment companies under ASC 946,
and that the financial statements have been prepared in accordance with ASC 946.

Response:
In future filings, Daxor will disclose in the Notes that Daxor follows the accounting and reporting requirements of investment
companies under ASC 946, and that the financial statements have been prepared in accordance with ASC 946.

15.
The table disclosing information about management should reflect the number of portfolios overseen by the directors, and the term
of office of each director and officer. Please revise the table to provide this information.

Response:
In future filings, Daxor will disclose the requested information.

U.S.
                                         Securities and Exchange Commission

July
13, 2020

Page
6

16.
Item 4(a)-(d) of Form N-CSR requires disclosure of the audit fees, audit-related fees, tax fees, and all other fees for the last
two fiscal years. Only one year was disclosed. Please ensure that two years are disclosed.

Response:
In future filings, Daxor will disclose two years.

17.
Item 4(c) of Form N-CSR requires that the nature of the tax services be described. Please ensure that the nature of these services
is described in more detail. Also, please note that audit-related fees and other fees are subject to similar requirements.

Response:
In future filings, Daxor will disclose more detail regarding the nature of these services.

18.
Even though Daxor does not have a portfolio manager, Item 8 of Form N-CSR applies. Please ensure that this disclosure is provided,
as appropriately tailored to address Daxor’s circumstances.

Response:
In future filings, Daxor will provide this disclosure, as appropriately tailored to address Daxor’s comments.

19.
Please revise the disclosure to address the following:

    ●
    Rule
    6-03(h)(2)(iv) of Regulation S-X, which addresses the aggregate cost of investments for Federal income tax purposes.

    ●
    Rule
    12-13 of Regulation S-X, which addresses option disclosure regarding the counterparty, if not exchange traded, and the notional
    amount.

    ●
    Please
    explain why the following statement is included in the Financial Highlights table, as this filing is the annual report to
    shareholders: “The annual financial information will be included in the Company’s annual rep